Credit Suisse’s CRISPR Therapeutics CRSP Stock Holding History

Credit Suisse’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-27,100	Closed	-$2.05M	–	3734
2021 Q4	$2.05M	Sell	27,100 -300	-1%	-$26.2K	﹤0.01%	2768
2021 Q3	$3.07M	Sell	27,400 -2,200	-7%	-$276K	﹤0.01%	2474
2021 Q2	$4.79M	Sell	29,600 -9,700	-25%	-$1.18M	﹤0.01%	2110
2021 Q1	$4.79M	Buy	+39,300	New	+$5.93M	﹤0.01%	2100
2020 Q4	–	Sell	-3,100	Closed	-$259K	–	4348
2020 Q3	$259K	Buy	+3,100	New	+$275K	﹤0.01%	3729

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse's CRSP Position: Q1 2024 in Review

Credit Suisse reduced its CRISPR Therapeutics (CRSP) stake by 18% in Q1 2024, selling an estimated $11.2M and leaving 719,309 shares worth $49M. The position accounts for 0.05% of the portfolio, ranked #378.

Credit Suisse first reported a position in CRSP in Q1 2017 and has held it in 29 quarters since. The position peaked at $156M in Q2 2021. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

Credit Suisse held 719,309 shares of CRISPR Therapeutics worth $49M as of Q1 2024.
Credit Suisse sold 156,836 CRISPR Therapeutics shares in Q1 2024, an estimated $11.2M.
CRISPR Therapeutics made up 0.05% of Credit Suisse's portfolio in Q1 2024, its #378 holding.
Credit Suisse first reported a position in CRISPR Therapeutics in Q1 2017 and has held it in 29 quarters since.
Credit Suisse's CRISPR Therapeutics position peaked at $156M in Q2 2021.
484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.